DE60108068D1 - Behandlung diabetischer ulcera - Google Patents

Behandlung diabetischer ulcera

Info

Publication number
DE60108068D1
DE60108068D1 DE60108068T DE60108068T DE60108068D1 DE 60108068 D1 DE60108068 D1 DE 60108068D1 DE 60108068 T DE60108068 T DE 60108068T DE 60108068 T DE60108068 T DE 60108068T DE 60108068 D1 DE60108068 D1 DE 60108068D1
Authority
DE
Germany
Prior art keywords
diabetic
treatment
ulcera
ulcers
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60108068T
Other languages
English (en)
Other versions
DE60108068T2 (de
Inventor
E Wood
John Davies
Lewis Siegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Application granted granted Critical
Publication of DE60108068D1 publication Critical patent/DE60108068D1/de
Publication of DE60108068T2 publication Critical patent/DE60108068T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60108068T 2000-01-11 2001-01-11 Behandlung diabetischer ulcera Expired - Fee Related DE60108068T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0000561.1A GB0000561D0 (en) 2000-01-11 2000-01-11 Treatment of diabetic ulcers
GB0000561 2000-01-11
PCT/IB2001/000018 WO2001051042A2 (en) 2000-01-11 2001-01-11 Treatment of diabetic ulcers

Publications (2)

Publication Number Publication Date
DE60108068D1 true DE60108068D1 (de) 2005-02-03
DE60108068T2 DE60108068T2 (de) 2005-12-08

Family

ID=9883498

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60108068T Expired - Fee Related DE60108068T2 (de) 2000-01-11 2001-01-11 Behandlung diabetischer ulcera

Country Status (15)

Country Link
US (1) US20030176442A1 (de)
EP (1) EP1248623B1 (de)
JP (1) JP2003519652A (de)
KR (1) KR20020082841A (de)
AT (1) ATE285775T1 (de)
AU (1) AU2540301A (de)
CA (1) CA2396120A1 (de)
DE (1) DE60108068T2 (de)
ES (1) ES2233599T3 (de)
GB (1) GB0000561D0 (de)
HU (1) HUP0204097A2 (de)
IL (1) IL150395A0 (de)
NZ (1) NZ519722A (de)
WO (1) WO2001051042A2 (de)
ZA (1) ZA200205694B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020588D0 (en) * 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
MXPA05009242A (es) * 2003-03-17 2006-04-18 Pfizer Prod Inc Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5.
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
US10143694B2 (en) 2006-10-27 2018-12-04 Matthew H. Kopacki Advanced formulations and therapies for treating hard-to-heal wounds
US20090163504A1 (en) * 2006-10-27 2009-06-25 Kopacki Matthew H Method for healing a wound using a phosphodiesterase type five inhibitor
WO2011126250A2 (ko) * 2010-04-05 2011-10-13 에스케이케미칼 주식회사 Pde5 억제제를 함유하는 피부 주름 개선용 조성물
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9612434A (pt) * 1995-12-28 1999-12-28 Fujiwasa Pharmaceutical Co Ltd Derivados de benzimidazol
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6251904B1 (en) * 1998-04-20 2001-06-26 Pfizer Inc. Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
IT1312310B1 (it) * 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
US20030105108A1 (en) * 2002-12-19 2003-06-05 Wood Ralph E. Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds

Also Published As

Publication number Publication date
WO2001051042A2 (en) 2001-07-19
DE60108068T2 (de) 2005-12-08
IL150395A0 (en) 2002-12-01
ZA200205694B (en) 2003-08-11
ATE285775T1 (de) 2005-01-15
EP1248623A2 (de) 2002-10-16
HUP0204097A2 (hu) 2003-04-28
AU2540301A (en) 2001-07-24
CA2396120A1 (en) 2001-07-19
ES2233599T3 (es) 2005-06-16
GB0000561D0 (en) 2000-03-01
EP1248623B1 (de) 2004-12-29
JP2003519652A (ja) 2003-06-24
NZ519722A (en) 2004-12-24
KR20020082841A (ko) 2002-10-31
US20030176442A1 (en) 2003-09-18
WO2001051042A3 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
EP1129706A3 (de) Verwendung von cGMP-PDE5-Hemmern zur Behandlung der Neuropathie
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
CY1110784T1 (el) Ιατρικη χρηση της τετρα-υδροτριαζολο[4,3-α]πυραζινης
ATE283856T1 (de) Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
HN2002000317A (es) Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
TR199901905T2 (xx) 2-(P�rin-9-il)-tetrahidrofuran-3,4-diol t�revleri.
DK1200418T3 (da) Nematodicide trifluorbutener
DE69911448D1 (de) Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
DE60108068D1 (de) Behandlung diabetischer ulcera
BR0307410A (pt) Uso de inibidores de pde5 no tratamento da cicatrização e fibrose
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
SE0004101D0 (sv) New use
DE60111254D1 (de) Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation
MY127989A (en) Treatment of neuropathy
CY1111319T1 (el) Ενωση 4-μεθυλεξανοϊκης κααλαλιδης f
SE0202608D0 (sv) New sequences

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee